Influence of Bromocriptin on Cardiac Valve in Patients with Pituitary Prolactinoma_West China Medical Journal

Authors：

 ZHONGChuan-hong ¹ , LIUDan ² , PENGYing ² , ZHOUPei-zhi ¹ ,  JIANGShu ¹

1. Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

JIANGShu, Email: jiangshu2000@126.com

Keywords：

Bromocriptine; Pituitary prolactinoma; Cardiac valve disease

DOI：

10.7507/1002-0179.20140141

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the risk of cardiac valve regurgitation in patients with pituitary prolactinoma treated with bromocriptine for a long time. Methods Between January 2012 and February 2013, 26 pituitary prolactinoma patients treated with bromocriptine for at least 6 months were included in the observation group, and 101 healthy people were regarded as the control group. Transthoracic echocardiography were performed on these patients for cardiac regurgitation, and the echocardiographic data were compared between the two groups. Results Trace tricuspid regurgitation was presented in 38.46% of patients in the observation group, and 19.80% of the controls (P=0.046). Interventricular septum thickness was (8.62±0.31) mm in patients in the observation group, and it was (8.57±0.12) mm in the controls (P=0.042). Conclusion No clinical significant cardiac valve regurgitation has been observed in pituitary prolactinoma patients treated by bromocriptin for a long time. Long-term echocardiographic follow-up of these patients is necessary.

Citation： ZHONGChuan-hong, LIUDan, PENGYing, ZHOUPei-zhi, JIANGShu. Influence of Bromocriptin on Cardiac Valve in Patients with Pituitary Prolactinoma. West China Medical Journal, 2014, 29(3): 467-469. doi: 10.7507/1002-0179.20140141 Copy

1.	Colao A, Savastano S. Medical treatment of prolactinomas[J]. Nat Rev Endocrinol, 2011, 7(5):267-278.
2.	Steiger M, Jost W, Grandas F, et al. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease:a systematic review[J]. J Neural Transm, 2009, 116(2):179-191.
3.	Rasmussen VG, Østergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists[J]. Mov Disord, 2011, 26(5):801-806.
4.	Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment[J]. Eur J Endocrinol, 2012, 167(1):17-25.
5.	Boguszewski CL, dos Santos CM, Sakamoto KS, et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease inc patients with prolactinomas[J]. Pituitary, 2012, 15(1):44-49.
6.	Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia:a meta-analysis from clinical studies[J]. J Endocrinol Invest, 2008, 31(12):1119-1123.
7.	Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma[J]. Clin Endocrinol (Oxf), 2009, 70(1):104-108.
8.	Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma[J]. J Clin Endocrinol Metab, 2008, 93(9):3348-3356.
9.	Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline[J]. J Clin Endocrinol Metab, 2008, 93(10):3777-3784.
10.	Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia[J]. Clin Endocrinol (Oxf), 2010, 73(3):369-374.
11.	Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia[J]. Int J Clin Pract, 2008, 62(12):1864-1869.
12.	Halperin I, Aller J, Varela C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma[J]. Clin Endocrinol (Oxf), 2012, 77(2):275-280.
13.	Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas[J]. Pituitary, 2009, 12(3):153-157.
14.	Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study[J]. Clin Endocrinol (Oxf), 2012, 77(1):99-105.

1. Colao A, Savastano S. Medical treatment of prolactinomas[J]. Nat Rev Endocrinol, 2011, 7(5):267-278.
2. Steiger M, Jost W, Grandas F, et al. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease:a systematic review[J]. J Neural Transm, 2009, 116(2):179-191.
3. Rasmussen VG, Østergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists[J]. Mov Disord, 2011, 26(5):801-806.
4. Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment[J]. Eur J Endocrinol, 2012, 167(1):17-25.
5. Boguszewski CL, dos Santos CM, Sakamoto KS, et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease inc patients with prolactinomas[J]. Pituitary, 2012, 15(1):44-49.
6. Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia:a meta-analysis from clinical studies[J]. J Endocrinol Invest, 2008, 31(12):1119-1123.
7. Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma[J]. Clin Endocrinol (Oxf), 2009, 70(1):104-108.
8. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma[J]. J Clin Endocrinol Metab, 2008, 93(9):3348-3356.
9. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline[J]. J Clin Endocrinol Metab, 2008, 93(10):3777-3784.
10. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia[J]. Clin Endocrinol (Oxf), 2010, 73(3):369-374.
11. Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia[J]. Int J Clin Pract, 2008, 62(12):1864-1869.
12. Halperin I, Aller J, Varela C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma[J]. Clin Endocrinol (Oxf), 2012, 77(2):275-280.
13. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas[J]. Pituitary, 2009, 12(3):153-157.
14. Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study[J]. Clin Endocrinol (Oxf), 2012, 77(1):99-105.

Previous Article
基层医院感染控制活动周的探讨
Next Article
The Relationship between Antioxidant Activity of Hyper Density Lipoprotein and Microalbuminuria in Patients with Hypertension

West China Medical Journal

Influence of Bromocriptin on Cardiac Valve in Patients with Pituitary Prolactinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content